New strategy targets antibiotic resistance in cystic fibrosis
Drug Target Review
Last updated: April 23, 2026
Researchers at the University of Texas at Austin have discovered a novel method to combat antimicrobial resistance by targeting a specific bacterial protein-folding pathway. This approach has shown promise in disabling resistance mechanisms and restoring antibiotic susceptibility in bacteria.
- Researchers identified that inhibiting the bacterial protein chaperone GroEL effectively blocks the emergence and maintenance of antibiotic resistance.
- This targeted inhibition was shown to restore the effectiveness of existing antibiotics against multi-drug resistant pathogens.
- The study also indicated that disabling GroEL can overcome cross-protection, a phenomenon where resistance to one antibiotic confers resistance to others.
- This breakthrough offers a potential new strategy for developing treatments against the growing global threat of antibiotic resistance.
- The findings suggest that focusing on essential bacterial processes like protein folding, rather than solely on developing new antibiotics, could be a more sustainable solution.
- This research opens avenues for re-sensitizing bacteria to previously ineffective drugs.
- The implications extend to various bacterial infections that are becoming increasingly difficult to treat.
- Further research is anticipated to explore the clinical application of this targeting strategy.
